Prime Medicine ($PRME) Stock Forecast: Up 8.4% Today

What is Prime Medicine?

Prime Medicine, Inc. (NASDAQ: PRME) is a biotechnology company specializing in the development of innovative therapies for various diseases. The company's stock showed a notable upward trend in the market today.

Why is Prime Medicine going up?

PRME stock is up 8.4% on Jun 30, 2026 14:06

• An upgrade from H.C. Wainwright to a Buy rating and a price target of $8 followed the approval of the Clinical Trial Application for PM577a. This development likely fueled the positive movement in the stock.
• Approval from New Zealand for the first clinical authorization of an in vivo Prime Editing therapy was a pivotal event that decreased perceived risks and bolstered investor confidence in the company's potential.
• LifeSci Capital maintained its Buy rating for Prime Medicine and retained a target price of $6, demonstrating ongoing optimism and endorsement of the company's growth opportunities. This show of faith possibly contributed to the stock's strong performance today.

PRME Price Chart

PRME Technical Analysis

PRME News

Price to book forward of Prime Medicine, Inc. – NASDAQ:PRME

This article briefly highlights the "Price to book forward" metric for Prime Medicine, Inc., traded under the NASDAQ:PRME symbol. It appears to be a financial data point from a larger platform, likely TradingView, indicating specific financial information for the company. The content itself is very minimal, focusing solely on this single financial metric.

https://www.tradingview.com/symbols/NASDAQ-PRME/financials-statistics-and-ratios/price-book-fwd/

H.C. Wainwright upgrades Prime Medicine stock rating to buy

H.C. Wainwright has upgraded Prime Medicine (NASDAQ:PRME) from Neutral to Buy, setting an $8.00 price target after New Zealand approved the Clinical Trial Application for PM577a, an investigational therapy for Wilson’s Disease. This clearance marks the first clinical authorization for an in vivo Prime Editing therapy from the company, enabling a global Phase 1/2 study to commence in the second half of 2026. Despite the stock being potentially overvalued according to InvestingPro data, and the company burning cash quickly, its strong current ratio offers liquidity, with H.C. Wainwright viewing the clinical clearance as a significant de-risking event.

https://www.investing.com/news/analyst-ratings/hc-wainwright-upgrades-prime-medicine-stock-rating-to-buy-93CH-4765072

LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6

LifeSci Capital has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained a target price of $6. The firm's analysis supports a positive outlook for the company.

https://www.moomoo.com/news/post/71891910/lifesci-capital-maintains-prime-medicine-prmeus-with-buy-rating-maintains

Trending Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 13.5% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.2% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 6.7% Today

fuboTV Inc. ($FUBO) Stock Forecast: Up 20.1% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 8.8% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 9.0% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.4% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 8.0% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Up 13.1% Today

Robert Half Inc. ($RHI) Stock Forecast: Up 8.2% Today

Prime Medicine Price History

16.05.2026 - PRME Stock was down 5.9%

• Prime Medicine reported a large net loss due to heavy R&D investment in its Prime Editing platform, which might have concerned investors and led to a bearish movement in the stock.
• The revenue growth in fiscal 2025 was overshadowed by the significant net loss, indicating that investors are cautious about the company's profitability in the near term.
• The presentation at the Goldman Sachs conference did not seem to have a positive impact on the stock, as the market might be waiting for concrete results or financial stability before reacting positively to the company's initiatives.

29.05.2026 - PRME Stock was up 8.4%

• Upgrade of PRME from Neutral to Buy, with a price target of $8.00, following approval of the Clinical Trial Application for PM577a, has significantly boosted investor confidence in the company.
• The approval for the global Phase 1/2 study of PM577a is seen as a major de-risking event, indicating positive progress in Prime Medicine's pipeline development.
• Despite concerns about potential overvaluation and cash burn rate, the strong current ratio and the promising outlook for PM577a have likely been key drivers behind today's bullish movement in PRME stock.

29.04.2026 - PRME Stock was up 6.5%

• Presence at the Jefferies Global Healthcare Conference probably boosted investor confidence in Prime Medicine's cutting-edge gene editing therapies.
• Concentration on creating curative genetic treatments for a range of medical fields might have garnered favorable interest from investors.
• The company's dedication to accurately fixing genetic mutations could have established it as a frontrunner in the biotechnology industry, fueling positive sentiment and stock price increase.

14.04.2026 - PRME Stock was down 5.1%

• PRME's Q1 report showed a loss and revenue below estimates, causing a downward market trend.
• The EPS of (28c) compared to the anticipated (25c) may have disappointed investors, influencing the bearish movement.
• While revenue exceeded predictions, the overall financial performance falling short of analysts' expectations could have triggered negativity among investors.
• H.C. Wainwright's hold rating and the projection of declining earnings along with significant revenue growth could have increased uncertainty, impacting PRME's stock price adversely.

08.04.2026 - PRME Stock was down 0.2%

• Today's decline in PRME stock could be attributed to various factors:
• The Q1 2026 net loss exceeding expectations might have sparked worries among investors regarding the company's financial stability and operational longevity.
• Despite positive regulatory filings and anticipated clinical data progress in its pipeline programs, the market could have been underwhelmed by the absence of significant revenue-generating milestones in the immediate future.
• While the hiring of a new CFO could be seen as a positive move for the company's leadership, it might have introduced an element of uncertainty affecting investor sentiment.
• Overall, today's market sentiment towards PRME appears to have been swayed more by immediate financial performance concerns rather than the future promise of its gene-editing technologies.

17.05.2026 - PRME Stock was up 6.9%

• PRME stock experienced a strong bullish movement likely due to positive analyst earnings forecasts and a majority "Buy" rating.
• The company's revenue growth in fiscal 2025 despite a net loss could have instilled confidence in investors about its long-term potential.
• Participation in prestigious events like the Goldman Sachs 47th Annual Global Healthcare Conference may have also contributed to the positive market sentiment surrounding PRME.
• Overall, the bullish movement could be attributed to a combination of favorable earnings forecasts, revenue growth, and industry recognition.

26.05.2026 - PRME Stock was up 8.9%

• A financial firm maintains a Buy rating for Prime Medicine and sets a target price of $6, indicating confidence in the company's growth prospects.
• The FDA granting Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, Prime Medicine's investigational therapy for chronic granulomatous disease (CGD), has likely boosted investor optimism.
• The RMAT designation expedites the development and review process for PM359, highlighting the potential for accelerated market entry and revenue generation.
• Positive Phase 1/2 clinical data and multiple fast-track designations emphasize the promising outlook for PM359 and Prime Medicine, driving investor interest and contributing to the bullish market movement.

04.05.2026 - PRME Stock was up 11.9%

• The bullish movement in PRME stock today could be attributed to the positive market sentiment generated by the announcement of the CEO's participation in the prestigious Goldman Sachs 47th Annual Global Healthcare Conference.
• Investors may view Prime Medicine's focus on developing innovative genetic therapies and its potential to repair a wide range of genetic mutations as a promising opportunity for growth and advancement in the biotechnology sector.
• The live audio webcast of the presentation may have increased investor confidence in the company's future prospects, leading to increased buying activity and driving the stock price higher.

09.05.2026 - PRME Stock was down 5.1%

• Concerns have arisen among investors due to the issuance of 75,000 stock options to multiple directors at Prime Medicine, possibly impacting the stock price by diluting existing shares.
• The stock options grant may be viewed by investors as a lack of short-term confidence in the company, which could be contributing to the current bearish movement.
• The rise in derivative securities holdings by directors might indicate a misalignment between management and shareholders, resulting in diminished investor confidence and a decrease in the stock's value.

11.04.2026 - PRME Stock was up 5.9%

• Despite reporting a Q1 loss and missing revenue estimates, Prime Medicine (PRME) experienced a bullish market movement today.
• The bullish trend could be attributed to the company's strategic initiatives, such as appointing new executives, initiating equity offerings, and prioritizing its liver disease programs.
• Analysts forecasting significant revenue growth and a higher price target for PRME might have also contributed to the positive market sentiment.
• Investors seem optimistic about Prime Medicine's gene-editing pipeline progress, promising preclinical data, and ongoing regulatory efforts, leading to the bullish movement in the stock.

30.05.2026 - PRME Stock was up 8.4%

• An upgrade from H.C. Wainwright to a Buy rating and a price target of $8 followed the approval of the Clinical Trial Application for PM577a. This development likely fueled the positive movement in the stock.
• Approval from New Zealand for the first clinical authorization of an in vivo Prime Editing therapy was a pivotal event that decreased perceived risks and bolstered investor confidence in the company's potential.
• LifeSci Capital maintained its Buy rating for Prime Medicine and retained a target price of $6, demonstrating ongoing optimism and endorsement of the company's growth opportunities. This show of faith possibly contributed to the stock's strong performance today.

24.05.2026 - PRME Stock was down 5.5%

• The bearish movement in PRME's stock could be attributed to profit-taking by investors after a series of positive news and designations from the FDA regarding their investigational therapy PM359 for chronic granulomatous disease (CGD).
• Despite the positive developments, the market may have reacted negatively due to potential concerns about the company's ability to successfully bring PM359 to market and generate significant revenue.
• Analysts' bullish sentiment on PRME prior to the bearish movement indicates that there was optimism surrounding the company, but short-term market fluctuations and profit-taking could have overshadowed this positive outlook.
• Overall, the bearish movement in PRME's stock today may be a temporary setback amidst a broader positive outlook for the company's innovative therapies in the healthcare sector.